< INDIETRO

Comunicati stampa

May 27, 2021

Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate

May 17, 2021

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

March 12, 2021

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate

February 22, 2021

Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate

December 11, 2020

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly

October 28, 2020

Sanofi and GSK to support COVAX with 200 million doses of adjuvanted, recombinant protein-based COVID-19 vaccine

October 15, 2020

Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody levels in preclinical studies

September 22, 2020

Sanofi and GSK sign agreements with the Government of Canada to supply up to 72 million doses of adjuvanted COVID-19 vaccine

September 18, 2020

Sanofi and GSK will provide up to 300 million doses of COVID-19 vaccine to the European Union